# Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

> **NCT00979615** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 129 (actual)

## Conditions studied

- Vasomotor Rhinitis

## Interventions

- **DRUG:** Olopatadine HCL (Patanase) Nasal Spray, 0.6%
- **DRUG:** Azelastine HCl (Astelin) Nasal Spray, 137 mcg

## Key facts

- **NCT ID:** NCT00979615
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-11
- **Final completion:** —
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2011-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979615, "Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00979615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*